The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment
Abstract Background The exact pathogenesis of Huntington’s disease (HD) remains unclear. However, mitochondrial dysfunction and oxidative stress are supposed to play a significant role. The objective of this study was to examine the possible neuroprotective effect of Lisinopril (Lisino) in a 3-nitro...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-11-01
|
Series: | Future Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43094-024-00724-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1846172174761590784 |
---|---|
author | Hanaa Wanas Mostafa Adel Rabie Basma Emad Aboulhoda Nagwa Mahmoud Ramadan Sahar Abdelwahab Sara Sayed Kadry Abdallah Eid Nassar Ali Leyan Nasruddeen Khayruddeen Yasir Hassan Elhassan Hadel Mahroos Alghabban Shaimaa Mohamed Abdelsalam Amira Karam Khalifa |
author_facet | Hanaa Wanas Mostafa Adel Rabie Basma Emad Aboulhoda Nagwa Mahmoud Ramadan Sahar Abdelwahab Sara Sayed Kadry Abdallah Eid Nassar Ali Leyan Nasruddeen Khayruddeen Yasir Hassan Elhassan Hadel Mahroos Alghabban Shaimaa Mohamed Abdelsalam Amira Karam Khalifa |
author_sort | Hanaa Wanas |
collection | DOAJ |
description | Abstract Background The exact pathogenesis of Huntington’s disease (HD) remains unclear. However, mitochondrial dysfunction and oxidative stress are supposed to play a significant role. The objective of this study was to examine the possible neuroprotective effect of Lisinopril (Lisino) in a 3-nitropropionic acid-produced HD in rats. Methods Sixty-four rats were divided into four groups (16/group): Group (1): Normal control group, Group (2): Lisinopril control group, Group (3): 3-NP non-treated group, and Group (4): (3-NP + Lisinopril) group. Behavior assessments (open field test, rotarod test, grip strength test) were performed along with different histological and biochemical parameters. Results Lisinopril upregulated the expression of the ACE2/Ang1-7/MAS receptor (MasR) axis of RAS, which triggered the PI3K/Akt pathway and prompted the CREB/BDNF neurogenesis signal. Furthermore, Lisinopril remarkably downregulated the inflammatory cytokines (NF-κB, TNF-α, IFN-γ and IL-6), decreased apoptotic markers (p53, BAX/Bcl2 ratio, Cyt-c and caspase-3) and upgraded the mitochondrial TFAM content and SDH activity along with restoration of the redox mechanism by recovering SOD, catalase, GSH and Nrf2. Conclusion Notably, the outcomes of this study disclosed that Lisinopril could be a future neuroprotective therapeutic candidate against HD. |
format | Article |
id | doaj-art-6f44e7a5b7074e54bd780b4c933652d2 |
institution | Kabale University |
issn | 2314-7253 |
language | English |
publishDate | 2024-11-01 |
publisher | SpringerOpen |
record_format | Article |
series | Future Journal of Pharmaceutical Sciences |
spelling | doaj-art-6f44e7a5b7074e54bd780b4c933652d22024-11-10T12:11:50ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532024-11-0110112210.1186/s43094-024-00724-zThe potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatmentHanaa Wanas0Mostafa Adel Rabie1Basma Emad Aboulhoda2Nagwa Mahmoud Ramadan3Sahar Abdelwahab4Sara Sayed Kadry Abdallah5Eid Nassar Ali6Leyan Nasruddeen Khayruddeen7Yasir Hassan Elhassan8Hadel Mahroos Alghabban9Shaimaa Mohamed Abdelsalam10Amira Karam Khalifa11Department of Medical Pharmacology, Faculty of Medicine, Cairo UniversityDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo UniversityDepartment of Medical Anatomy and Embryology, Faculty of Medicine, Cairo UniversityDepartment of Medical Physiology, Faculty of Medicine, Cairo UniversityDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo UniversityDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo UniversityDepartment of Medical Anatomy and Embryology, Faculty of Medicine, Cairo UniversityDepartment of Basic Medical Science, College of Medicine, Taibah UniversityDepartment of Basic Medical Science, College of Medicine, Taibah UniversityDepartment of Basic Medical Science, College of Medicine, Taibah UniversityDepartment of Anatomic Pathology, Faculty of Medicine, Cairo UniversityDepartment of Medical Pharmacology, Faculty of Medicine, Cairo UniversityAbstract Background The exact pathogenesis of Huntington’s disease (HD) remains unclear. However, mitochondrial dysfunction and oxidative stress are supposed to play a significant role. The objective of this study was to examine the possible neuroprotective effect of Lisinopril (Lisino) in a 3-nitropropionic acid-produced HD in rats. Methods Sixty-four rats were divided into four groups (16/group): Group (1): Normal control group, Group (2): Lisinopril control group, Group (3): 3-NP non-treated group, and Group (4): (3-NP + Lisinopril) group. Behavior assessments (open field test, rotarod test, grip strength test) were performed along with different histological and biochemical parameters. Results Lisinopril upregulated the expression of the ACE2/Ang1-7/MAS receptor (MasR) axis of RAS, which triggered the PI3K/Akt pathway and prompted the CREB/BDNF neurogenesis signal. Furthermore, Lisinopril remarkably downregulated the inflammatory cytokines (NF-κB, TNF-α, IFN-γ and IL-6), decreased apoptotic markers (p53, BAX/Bcl2 ratio, Cyt-c and caspase-3) and upgraded the mitochondrial TFAM content and SDH activity along with restoration of the redox mechanism by recovering SOD, catalase, GSH and Nrf2. Conclusion Notably, the outcomes of this study disclosed that Lisinopril could be a future neuroprotective therapeutic candidate against HD.https://doi.org/10.1186/s43094-024-00724-zHuntington’s diseaseRenin–angiotensin systemLisinoprilMitochondrial dysfunction3-nitropropionic acid |
spellingShingle | Hanaa Wanas Mostafa Adel Rabie Basma Emad Aboulhoda Nagwa Mahmoud Ramadan Sahar Abdelwahab Sara Sayed Kadry Abdallah Eid Nassar Ali Leyan Nasruddeen Khayruddeen Yasir Hassan Elhassan Hadel Mahroos Alghabban Shaimaa Mohamed Abdelsalam Amira Karam Khalifa The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment Future Journal of Pharmaceutical Sciences Huntington’s disease Renin–angiotensin system Lisinopril Mitochondrial dysfunction 3-nitropropionic acid |
title | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment |
title_full | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment |
title_fullStr | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment |
title_full_unstemmed | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment |
title_short | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment |
title_sort | potential therapeutic role of lisinopril in augmenting the striatal neuroplasticity via the striatal ace2 ang1 7 mas receptor axis in 3 nitropropionic acid induced huntington s disease in rats shifting paradigms in huntington s disease treatment |
topic | Huntington’s disease Renin–angiotensin system Lisinopril Mitochondrial dysfunction 3-nitropropionic acid |
url | https://doi.org/10.1186/s43094-024-00724-z |
work_keys_str_mv | AT hanaawanas thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT mostafaadelrabie thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT basmaemadaboulhoda thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT nagwamahmoudramadan thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT saharabdelwahab thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT sarasayedkadryabdallah thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT eidnassarali thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT leyannasruddeenkhayruddeen thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT yasirhassanelhassan thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT hadelmahroosalghabban thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT shaimaamohamedabdelsalam thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT amirakaramkhalifa thepotentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT hanaawanas potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT mostafaadelrabie potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT basmaemadaboulhoda potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT nagwamahmoudramadan potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT saharabdelwahab potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT sarasayedkadryabdallah potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT eidnassarali potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT leyannasruddeenkhayruddeen potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT yasirhassanelhassan potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT hadelmahroosalghabban potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT shaimaamohamedabdelsalam potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment AT amirakaramkhalifa potentialtherapeuticroleoflisinoprilinaugmentingthestriatalneuroplasticityviathestriatalace2ang17masreceptoraxisin3nitropropionicacidinducedhuntingtonsdiseaseinratsshiftingparadigmsinhuntingtonsdiseasetreatment |